Background {#Sec1}
==========

Fibromyalgia (FM) \[[@CR1]\] is characterized by chronic pain, tenderness \[[@CR2]\], and pain amplification \[[@CR3]--[@CR5]\]. Increased levels of inflammatory cytokines \[[@CR6]\] and changes in neurotropic growth factors in the central nervous system and peripherally may influence the development and maintenance of central pain hypersensitivity by affecting adaptation and neuroplasticity \[[@CR7]--[@CR10]\]. This condition leads to considerable activity limitations and is very difficult to treat effectively.

Clinical experience and current research indicate that exercise is beneficial in FM and exercise was recently recommended as first line treatment ahead of pharmacological treatment \[[@CR11]\]. However, meta-analysis in a Cochrane review of resistance exercise is based on few trials \[[@CR12]\]. Planning exercise for patients with FM is challenging due to activity-induced pain at the initial phase both during isometric \[[@CR13]\] and aerobic exercise \[[@CR14]\]. However, we have previously reported positive changes in symptoms and strength after resistance exercise for the complete set of 130 patients participating in a multicenter randomized controlled trial \[[@CR15]\]. Pain and strength \[[@CR15]\] and fatigue were improved \[[@CR16]\]. Furthermore, a number of independent studies indicate that resistance exercise for patients with FM is safe and effective \[[@CR15], [@CR17], [@CR18]\].

Our previous studies show that improvement in symptoms after aerobic exercise was reduced and delayed among obese FM patients with apparent involvement of the metabolic factors, insulin-like growth factor (IGF-1) and leptin \[[@CR7], [@CR19]\]. However, a previous resistance exercise study showed unaltered levels of basal serum hormones including IGF-1 \[[@CR20]\]. Obesity is common in FM, with a prevalence between 40 and 70% \[[@CR21]--[@CR23]\] and is correlated with higher levels of pain and fatigue \[[@CR22], [@CR24]--[@CR26]\]. In the related syndrome of chronic fatigue, symptom severity is also associated with increased BMI and with the presence of metabolic syndrome \[[@CR27]\]. There is an inverse relation between BMI and total IGF-1 levels \[[@CR28], [@CR29]\] and a deregulation of growth hormone/IGF-1 signaling in obesity \[[@CR30], [@CR31]\]. IGF-1 plays a key role in the adaptation to exercise \[[@CR32]\] by regulating metabolic activity and cell proliferation in skeletal muscle and other peripheral tissues and in the central nervous system (CNS) \[[@CR33], [@CR34]\]. Up to one third of FM patients are estimated to suffer from growth hormone \[[@CR35]\] deficiency and reduced IGF-1 \[[@CR36]--[@CR38]\].

Leptin is another important metabolic factor, it is a central regulator of satiety and body weight \[[@CR39], [@CR40]\] and is also involved in regulation of emotional responses \[[@CR41]--[@CR45]\] and pain \[[@CR46]\]*.* Serum leptin is taken up into the CNS via the blood--brain barrier and the diurnal rhythm of leptin secretion is dependent on energy availability and is influenced by growth hormone, insulin and cortisol \[[@CR47]\]. Leptin receptors are distributed in multiple regions in the CNS including the hippocampus, the hypothalamus \[[@CR48]\] and multiple thalamic nuclei \[[@CR49]\], reflecting the multiple roles of leptin.

The purpose of the study was to investigate how metabolic factors contribute to the effects of resistance exercise in patients with FM. Our hypothesis was that there may be a reduced response to resistance exercise in the overweight and obese women with FM compared to lean women and that the metabolic factors IGF-1 and leptin may be involved in this difference.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a substudy of a previously reported randomized controlled multicenter trial \[[@CR15]\] (ClinicalTrials.gov identification number: NCT01226784) studying the effects of a progressive resistance exercise program \[[@CR15]\]. This longitudinal and observatory substudy focused on biological and clinical changes after resistance exercise.

The rationale of the resistance exercise program was to improve muscle strength and health status by progressive resistance exercise, but to minimize the risk of increased pain while loading the muscles. The 15-week exercise program twice a week has previously been described in detail \[[@CR15]\]. Exercise was performed under the supervision of experienced physiotherapists according to the principles of person-centered care \[[@CR50]\]. Thus, the exercise program and its progression was individually planned with each patient and modified according to individual resources. Exercise was preceded by an individual meeting to discuss the patient's goals, her previous experiences and possible obstacles for exercise. One repetition maximum (1RM) was tested, and the initial load of each exercise was defined with each patient and starting at 40% of 1RM. Each session was initiated with a 10 min warm-up period, followed by resistance exercise for legs, arms and hands and core stability and ended with stretching exercise. After 3--4 weeks the load was increased to 60% and thereafter to 80% of 1RM. Explosive strength exercises for legs were included at 5 and 8 weeks, as described previously \[[@CR15]\]. Exercise was conducted in groups of 5--7 patients and lasted for about 1 hour.

Participants {#Sec4}
------------

### Criteria for inclusion {#Sec5}

Women with FM, aged 20 to 65 years and who were able to participate in the assigned exercise twice a week for 15 weeks. The women were screened for eligibility by an experienced physician to verify ACR 1990 criteria for FM by means of a standardized interview and palpation of tender points \[[@CR2]\]. Participation with blood samples was optional in the primary trial. All participants were offered to participate with blood samples and the ability to participate with blood samples at baseline and after the exercise period \[[@CR15]\] was an additional inclusion criteria in this substudy.

### Criteria for exclusion {#Sec6}

As described previously \[[@CR15]\], exclusion criteria were high blood pressure (\>160/90 mmHg), osteoarthritis in hip or knee, confirmed by radiological findings and affecting activities of daily life such as stair climbing or walking, other severe somatic or psychiatric disorders, other dominating causes of pain than FM, high consumption of alcohol (alcohol use disorders identification test (AUDIT) score \>6) \[[@CR32]\], participation in a rehabilitation program within the past year, regular resistance exercise or relaxation exercise twice a week or more, inability to understand or speak Swedish, and not being able to refrain from analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) or hypnotic drugs for 48 h prior to examinations.

Forty-three women with FM, were examined at baseline and after 15 weeks of the intervention (post-test). Serum was collected at rest at baseline and at post-test.

For patient characteristics, see Table [1](#Tab1){ref-type="table"}. Lean patients were defined as BMI below 25 kg/m^2^ and BMI ranged from 20.9 to less than 25.0 kg/m^2^; overweight patients had BMI from 25.0 to 29.9 kg/m^2^. Obese patients had BMI **≥**30.0 kg/m^2^, with a range of 30.3 to 39.5 kg/m^2^ \[[@CR51]\].Table 1Characteristics of the study populationCharacteristicsAll patients\
*n* = 43Lean\
*n* = 18Overweight\
*n* = 17Obese\
*n* = 8*p* Value^a^\
Lean vs overweight*p* Value^a^\
Lean vs obese*p* Value^a^\
Overweight vs obeseAge (years)51 (25 to 64)50 (25 to 63)53 (34 to 64)51 (25 to 63)0.3510.8070.711BMI (kg/m^2^)25.6 (20.9 to 39.9)23.1 (20.9 to 24.96)26.2 (25.1 to 29.9)35.2 (30.8 to 39.9)**\<0.001\<0.001\<0.001**Symptom duration (years)9 (0 to 35)8 (1 to 20)10 (0 to 35)7 (1 to 26)0.3860.8920.628Tender points (n)16 (11 to 18)16 (12 to 18)16 (11 to 18)17 (15 to 18)0.9090.3110.238Pharmacologic treatment, N (%)*p* Value^b^ Lean vs overweight*p* Value^b^\
Lean vs obese*p* Value^b^\
Overweight vs obeseNSAID/paracetamol34 (79)12 (67)15 (88)7 (88)0.2640.5310.958Opioids for mild to moderate pain. Yes6 (14)2 (11)3 (18)1 (12)0.9450.9180.743Antidepressants. Yes22 (51)8 (44)11 (65)3 (38)0.38800.7410.397Anticonvulsives. Yes4 (9)2 (11)2 (6)1 (12)0.95160.9180.958Sedatives. Yes7 (16)3(17)4 (24)0 (0)0.93260.5740.362Lean patients had BMI from 20.9 to \< 25.0 kg/m^2^; overweight patients had BMI 25.0 to 29.9 kg/m^2^. Obese patients had BMI **≥**30.0 kg/m^2^. Median values and range (min, max). Furthest to the right is shown group comparisons (*p*-value; ^a^Mann-Whitney *U*-test. ^b^Chi-square test with Yates correction). *P*-value in bold type is significant

Clinical measurements {#Sec7}
---------------------

Current pain at the time of interview was rated on a visual analogue scale (0--100). Fatigue during the previous week was rated with the Multidimensional Fatigue Inventory (MFI-20) \[[@CR52]\] subscale of General Fatigue (MFIGF, range 4--20), which estimates fatigue by questions related to feeling "fit", "tired" and "rested". A higher score indicates more severe pain or fatigue.

Maximal isometric knee extension force (N) was measured with *Steve Strong® (Stig Starke HBI, Göteborg, Sweden)*, a dynamometer. The participant was in a fixed seated position with knee and hip in 90° of flexion. A non-elastic strap was attached to a pressure transducer with an amplifier. A mean value of three trials from the right and left leg was calculated \[[@CR53], [@CR54]\]. Average maximal isometric elbow flexion force (kg) was measured with *Isobex® (Medical Device Solutions AG, Oberburg, Switzerland)*. The upper arm was aligned with the trunk and the elbow in 90° of flexion \[[@CR55]\]. A mean value from the right and left elbow flexion was calculated. *Grippit® (AB Detektor, Göteborg, Sweden)* is an electronic instrument that measures hand grip force (N). The mean force over 10 seconds was recorded \[[@CR56]\].

Laboratory analysis {#Sec8}
-------------------

Serum samples were acquired by venipuncture of the cubital vein. Collected blood samples were centrifuged at 1500 g for 30 min immediately after collection, aliquoted, and stored frozen at −70 °C until use. Biological markers were analyzed by sandwich enzyme-linked immunosorbent assays (ELISAs) using a pair of specific antibodies for human adiponectin (DY1065, 62 pg/mL), human leptin (DY389, 31 pg/mL), human resistin (DY1359, 10 pg/mL), human serum free bioactive IGF-1 (DY291, 4 pg/mL) and IGFBP3 (DY675, 0.125 ng/ml) which were all purchased from RnD Systems (Minneapolis, MN, USA). All assays were performed according to the instructions of the manufacturers. ELISAs were read with a Spectramax 340 from Molecular Devices (Sunnyvale, CA, USA). Serum total IGF-1 was measured by solid-phase, enzyme-labeled chemoluminescent immunoassay with IDS-iSYS IGF1 immunoassay (IS-3900, Immunodiagnostic Systems Boldon, UK) using the IDS-iSYS Multi-Discipline Immunoassay System (IS-310400, Immunodiagnostic Systems Boldon, UK).

Statistics {#Sec9}
----------

Descriptive data are presented as median and interquartile range (IQR). ∆-values represent the value of change between baseline and post-treatment examination. The Wilcoxon signed-rank test was used for comparisons of continuous variables within groups. Comparisons between groups were made using Mann--Whitney *U*-test. Effect size (Cohen's d) was calculated as d = (Mean after exercise-mean at baseline)/Pooled standard deviation. Chi-square test was used for comparison of categorical variables (pharmaceutical treatment). To control for possible type I errors, the upper limit of the expected number of false significant results for the analyses was calculated by the following formula:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
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where α is the significance level \[[@CR57]\]. All significance tests were two-sided and conducted at the 5% significance level. All significant tests were two-tailed, and values of *p* \< 0.05 were considered significant. All statistical evaluation of data was done with the statistic program IBM SPSS Statistics for Macintosh, Version 22.0 (IBM Corporation, Armonk, New York, USA).

Results {#Sec10}
=======

The participant characteristics are presented in Table [1](#Tab1){ref-type="table"}.

IGF-1 and adipokines {#Sec11}
--------------------

Baseline levels and change in IGF-1 and adipokines are presented in Table [2](#Tab2){ref-type="table"}. In the whole group, total IGF-1 (*p* = 0.018), IGFBP3 (*p* = 0.045) and leptin (*p* = 0.040) were reduced after 15 weeks. In parallel, free IGF-1 (*p* = 0.047), IGBP3 (*p* = 0.025) and leptin (*p* = 0.008) were significantly decreased in lean patients, but not in the overweight and the obese. Change in free IGF-1 was significantly different between lean and obese individuals after resistance exercise (*p* = 0.035). Change in leptin differed significantly between lean and overweight (*p* = 0.005). Changes in total-IGF-1 and IGFBP3 did not differ significantly between the groups.Table 2Serum levels of total IGF-1, serum free IGF-1, IGFBP3, adiponectin, leptin, and resistin at baseline, and change (∆) at posttest after resistance exerciseAll patientsLeanOverweightObeseIntergroup differences in changeBaseline∆PosttestBaseline∆PosttestBaseline∆PosttestBaseline∆PosttestLean vs overweightLean vs obeseOverweight vs obeseMedian (IQR)Median (IQR)Median (IQR)Median (IQR)Median\
(IQR)Median (IQR)Median (IQR)Median (IQR)Cohen's dCohen's dCohen's dCohen's d*P*-value^a^*P*-value^a^*P*-value^a^*P*-value^a^*P*-value^b^*P*-value^b^*P*-value^b^Total IGF-1137 (54)−3 (−21.2 to 5)135 (54)−11 (−18,8 to 5)151 (61)−3 (−47,5 to 7)137 (61)−1.5 (−18 to 8,8)(ng/ml)*n* = 42*n* = 42*n* = 18*n* = 18*n* = 16*n* = 16*n* = 8*n* = 8−0.23−0.2−0.36−0.09**0.018***p* = 0.076*p* = 0.147*p* = 0.528*p* = 0.986*p* = 0.531*p* = 0.528Free IGF-12.6 (3.2)0 (−1.4 to 1.0)3.3 (2.3)−0.7 (−1,9 to 0,1)2.6 (3.3)0.4 (−1,1 to 1,5)0.8 (2.3)0.4 (−0,6 to 2,8)(ng/ml)*n* = 43*n* = 43*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8−0.05−0.320.10.60.752***p***  **= 0.047***p* = 0.485*p* = 0.237*p* = 0.053***p***  **= 0.035***p* = 0.511IGFBP3823 (159)−46.4 (−84.4 to 33.2)828 (86)−56 (−97 to 5)790 (161)−47 (−86 to 119)858 (238)−41 (−73 to 23)(ng/ml)*n* = 43*n* = 43*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8−0.29−0.570.02−0.36***p***  **= 0.045*p***  **= 0.025***p* = 0.943*p* = 0.161*p* = 0.335*p* = 0.567*p* = 0.887Adiponectin10288 (6280)192 (−1880 to 2064)12036 (7396)224 (−1638 to 2406)11624 (5668)−832 (−1948 to 1752)6600 (4020)−204 (−2648 to 2398)(ng/ml)*n* = 43*n* = 43*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 80.020.09−0.03−0.040.819*p* = 0.586*p* = 0.813*p* = 0.889*p* = 0.59*p* = 0.765*p* = 0.887Leptin27.7 (71.6)−4.9 (−18.5 to 1.0)21 (86)−15.9 (−23,6 to −0,1)39 (60)0 (−3 to 19,6)23 (106)−12 (−23,1 to −2,3)(ng/ml)*n* = 43*n* = 43*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8−0.13−0.22−0.02−0.51**0.040*p***  **= 0.008***p* = 0.463*p* = 0.093***p***  **= 0.005***p* = 0.849***p***  **= 0.019**Resistin13.1 (5.1)−0.7 (−2.0 to 0.9)13 (5)−0.7 (−1.5 to 1)11 (7)0.2 (−2,5 to 1,6)15 (5)−1.6 (−1,9 to 0,1)(ng/ml)*n* = 43*n* = 43*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8−0.110.04−0.19−0.420.227*p* = 0.446*p* = 0.723*p* = 0.161*p* = 0.987*p* = 0.285*p* = 0.588Serum levels of the whole group and subdivided in lean, overweight and obese patients. Median values, upper and lower boundaries of the interquartile (IQR) range are indicated. Effect size of change is shown as Cohen's d. Within group comparisons (*p*-value^a^: Wilcoxon signed rank test) and group comparisons (*p*-value^b^: Mann--Whitney *U*-test) are shown. *P*-values in bold type are significant

Symptom severity and strength {#Sec12}
-----------------------------

Changes after resistance exercise in symptom severity and strength was assessed in lean (*n* = 18), overweight (*n* = 17) and obese individuals (*n* = 8), see Table [3](#Tab3){ref-type="table"}. Following resistance exercise the lean patients with FM improved with regard to current pain (*p* = 0.039) and general fatigue (∆MFIGF, *p* = 0.022). Elbow flexion force was also significantly improved in this group (*p* = 0.017) as well as in overweight (*p* = 0.049) and obese patients (*p* = 0.012). Symptoms did not improve in the overweight and the obese women. Changes in symptoms and muscle strength did not differ significantly between the groups.Table 3Clinical response to resistance exercise among lean, overweight and obese patientsLeanOverweightObeseDifferences in changeBaseline∆PosttestBaseline∆PosttestBaseline∆PosttestLean vs overweightLean vs obeseOverweight vs obeseMedian (IQR)Median (IQR)Median (IQR)Median (IQR)Median (IQR)Median (IQR)*P*-value^a^*P*-value^a^*P*-value^a^*P*-value^b^*P*-value^b^*P*-value^b^Current pain56 (43)−14.5 (−25,3 to 2,8)48 (39)−13 (−31,5 to 13,5)49 (17)1 (−37,3 to 16,5)(VAS)*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8***p***  **= 0.039***p* = 0.136*p* = 0.624*p* = 0.987*p* = 0.429*p* = 0.549MFIGF fatigue19 (2)−1 (−3 to 0)18 (4)−1 (−2 to 1)19 (4)−0.5 (−2,8 to 1)(4--20)*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8***p***  **= 0.022***p* = 0.303*p* = 0.443*p* = 0.757*p* = 0.567*p* = 0.842Hand grip force174 (110)8.8 (−6,4 to 30,4)165 (122)10.3 (−7,5 to 41,3)173 (144)14 (1,4 to 35,1)(N)*n* = 18*n* = 18*n* = 17*n* = 16*n* = 8*n* = 8*p* = 0.074*p* = 0.098*p* = 0.123*p* = 0.851*p* = 0.567*p* = 0.881Elbow flexion force12.9 (5.1)1.2 (0 to 3,6)11.1 (7.1)1.4 (−0,8 to 5,1)13.5 (10.6)3 (1,6 to 5,1)(kg)*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8***p***  **= 0.017*p***  **= 0.049*p***  **= 0.012***p* = 0.858*p* = 0.080*p* = 0.315Knee extension force338 (135)11.5 (−46,6 to 48,3)306 (136)43 (−31 to 74,3)389 (185)35.3 (−16,3 to 105,6)(N)*n* = 18*n* = 18*n* = 17*n* = 17*n* = 8*n* = 8*p* = 0.647*p* = 0.113*p* = 0.208*p* = 0.303*p* = 0.285*p* = 0.754Symptom severity and strength at baseline, and change (∆) at posttest after resistance exercise. Median values with upper and lower boundaries of the interquartile range are indicated Within group comparisons (*p*-value^a^: Wilcoxon signed rank test) and group comparisons (*p*-value^b^: Mann--Whitney *U*-test) are presented. *P*-values in bold type are significant

Type 1 error {#Sec13}
------------

Changes in IGF-1 and adipokines resistance exercise in the whole group and among lean, overweight and obese patients (Table [2](#Tab2){ref-type="table"}) comprised a total of 42 comparisons and the upper level of the number of false significant results was 1.7, which means that two of the nine significant results might be false.

Clinical response to resistance exercise among lean, overweight and obese patients (Table [3](#Tab3){ref-type="table"}) comprised a total of 30 comparisons and the upper level of the number of false significant results was 1.3, which means that one of the five significant results might be false.

Discussion {#Sec14}
==========

Recent publications have recommended resistance exercise for patients with FM \[[@CR17], [@CR18]\]. Since muscle strength is reduced in many women with FM, graded resistance exercise adjusted to health status and symptoms, appears to be important. Women with FM participating in a resistance exercise program have been found to improve in both symptoms and muscular strength \[[@CR15]\]. In the present substudy, the levels of free IGF-1, IGFBP3 and leptin were reduced in lean women with FM after 15 weeks of exercise, along with improvement in pain, fatigue and upper limb muscle strength. In overweight and obese women, levels of IGF-1 and adipokines as well as pain and fatigue were unchanged while upper limb muscle strength was increased.

The improvement in lean women with FM found in the present study is in line with a previous study where fatigue was reduced in lean women with FM after 15 weeks of aerobic exercise while symptom improvements were delayed in overweight and obese women with FM \[[@CR7]\]. In the same study, resting levels of IGFBP3 also tended to decrease in lean women with FM, free IGF-1 was unchanged while total IGF-1 increased following aerobic exercise \[[@CR7]\]. Resistance exercise by pharmacologically androgen-deprived men led to reduced IGF-1 and IGFBP3 and normalized leptin and adiponectin levels \[[@CR58]\] but IGF-1 levels were not altered in a study of resistance exercise in elderly women with FM \[[@CR20]\].

Changes in the metabolic factors IGF-1 and leptin in response to exercise may affect pain processing in the CNS. Recent studies indicate the involvement of hippocampus in response to exercise and in chronic pain. In FM, impaired executive function associates with reduced hippocampal activation \[[@CR59]\] and connectivity is decreased between pain areas and sensorimotor brain areas \[[@CR60]\]. The hippocampus is involved in chronic pain and FM \[[@CR61], [@CR62]\], participates in pain processing \[[@CR35], [@CR63]--[@CR66]\] and indicates neurotropic changes in FM \[[@CR67], [@CR68]\] and chronic pain \[[@CR69], [@CR70]\]. However, regular exercise leads to functional and neurotropic changes in the hippocampus \[[@CR71], [@CR72]\] and normalization of functional connectivity in women with FM \[[@CR73]\]. Hippocampal neurogenesis and neural plasticity is modulated by IGF-1 and other metabolic signals \[[@CR34]\]. The majority of studies on physical activity and the CNS involve aerobic exercise but resistance exercise has shown similar benefit in the CNS in terms of cognitive function \[[@CR74]\] and changes in the growth factors IGF-1 and brain-derived neurotrophic factor \[[@CR75]\]. Furthermore, in a group of elderly individuals physical activity levels but not aerobic fitness correlated with cognitive performance, increased prefrontal and cingulate gray matter and with levels of neurotrophic factor G-CSF \[[@CR76]\]. This indicates that resistance exercise will be sufficient and that cardiovascular exercise is not required. In concurrence, the beneficial effects of both resistance and aerobic exercise in FM on pain and fatigue may involve neurotropic and neuroprotective signaling in the hippocampus mediated by leptin \[[@CR72]\] and adaptation to exercise-induced peaks of IGF-1 \[[@CR19], [@CR77]--[@CR79]\].

High levels of leptin are suggested as a marker of leptin resistance involving both CNS and the periphery \[[@CR80]\]. Acute aerobic exercise downregulated leptin transcription in adipose tissue \[[@CR81]\] and leptin sensitivity in the CNS was improved \[[@CR82]\]. Decreased leptin levels following exercise may therefore indicate increased leptin sensitivity. In agreement, reduced leptin levels after 3 months \[[@CR83]\] and 6 months of resistance exercise was previously reported \[[@CR84]\]. Thus, improved leptin signaling seems to associate with exercise and reduced pain and fatigue.

Obesity is associated with reduced leptin sensitivity \[[@CR85]\]. In patients with type 2 diabetes, leptin levels were not altered after 6 weeks of resistance exercise \[[@CR86]\]. Possibly three months of progressively increased resistance exercise is also too short a duration to improve leptin receptor sensitivity in overweight patients. Thus, a longer period of exercise up to 6 months may be beneficial in patients with obesity.

The main limitation of this study is the small sample size of the BMI groups. However, the present results indicate that IGF-1 and leptin are involved in change of pain and fatigue in patients with FM after resistance exercise.

Conclusions {#Sec15}
===========

The clearest clinical response to resistance exercise was found in lean women with FM. In these individuals, individualized resistance exercise was followed by changes in IGF-1 and leptin, reduced pain, fatigue and improved upper limb muscular strength. In overweight and obese women with FM, markers of metabolic signaling and clinical symptoms were unchanged, but strength was improved. Resistance exercise combined with dietary interventions might benefit patients with FM and overweight.
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CNS

:   Central nervous system
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:   Insulin-like growth factor 1
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:   IGF-binding protein 3

MFIGF

:   Multidimensional fatigue inventory (MFI-20) subscale general fatigue

NSAIDs

:   Non-steroidal anti-inflammatory drugs
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